Subject Group | Mean, liters ± SD | Median, liters | Range, liters (min - max) |
---|---|---|---|
Baseline FEV 1 | Â | Â | Â |
All patients (n = 95) | 1.40 ± 0.71 | 1.19 | 3.09 (0.44 - 3.53) |
ceftaz/tobra treated (n = 50) | 1.37 ± 0.71 | 1.13 | 3.09 (0.44 - 3.53) |
mero/tobra treated (n = 45) | 1.44 ± 0.71 | 1.37 | 2.99 (0.48 - 3.47) |
FEV1 ≥ 70% predicted (n = 11) | 2.46 ± 0.87 | 2.72 | 2.38 (1.15 - 3.53) |
FEV1 40% - 69% predicted (n = 46) | 1.54 ± 0.56 | 1.47 | 2.52 (0.56 - 3.08) |
FEV1 < 40% predicted (n = 38) | 0.93 ± 0.30 | 0.90 | 1.43 (0.44 - 1.87) |
Observed Peak FEV 1 | Â | Â | Â |
All patients | 1.95 ± 0.87 | 1.72 | 3.62 (0.67 - 4.29) |
ceftaz/tobra treated | 1.83 ± 0.85 | 1.55 | 3.29 (0.67 - 3.96) |
mero/tobra treated | 2.09 ± 0.88 | 1.78 | 2.99 (0.48 - 4.29) |
FEV1 ≥ 70% predicted | 3.17 ± 1.01 | 3.71 | 2.99 (1.30 - 4.29) |
FEV1 40% - 69% predicted | 2.05 ± 0.71 | 2.05 | 2.76 (0.84 - 3.60) |
FEV1 < 40% predicted | 1.48 ± 0.59 | 1.39 | 2.44 (0.67 - 3.11) |
FEV 1 Change, Baseline to Peak | Â | Â | Â |
All patients | 0.55 ± 0.43 | 0.46 | 2.19 (0.0 - 2.19) |
ceftaz/tobra treated | 0.46 ± 0.36 | 0.39 | 1.50 (0.05 - 1.55) |
mero/tobra treated | 0.65 ± 0.49 | 0.55 | 2.19 (0.0 - 2.19) |
FEV1 ≥ 70% predicted | 0.70 ± 0.46 | 0.43 | 1.40 (0.15 - 1.55) |
FEV1 40% - 69% predicted | 0.51 ± 0.41 | 0.46 | 2.19 (0.0 - 2.19) |
FEV1 < 40% predicted | 0.56 ± 0.45 | 0.43 | 1.93 (0.01 - 1.94) |